购物车
- 全部删除
- 您的购物车当前为空
HJ445A是一种高效选择性的MYOF抑制剂,具有良好的水溶性,用于治疗胃癌。在MGC803和MKN45胃癌细胞中,HJ445A具有强大的抗增殖能力,其IC50值分别为0.16 μM和0.14 μM。此外,HJ445A与MYOF-C2D结构域结合,其KD值为0.17 μM,且能够通过逆转上皮-间充质转化(EMT)过程阻止胃癌细胞的迁移,并以浓度依赖的方式抑制MKN45细胞的集落形成。值得注意的是,与化合物6y相比,HJ445A的水溶性得到了显著提高,增强了约170倍。此外,HJ445A在体内也显示出了卓越的抗肿瘤效果。
HJ445A是一种高效选择性的MYOF抑制剂,具有良好的水溶性,用于治疗胃癌。在MGC803和MKN45胃癌细胞中,HJ445A具有强大的抗增殖能力,其IC50值分别为0.16 μM和0.14 μM。此外,HJ445A与MYOF-C2D结构域结合,其KD值为0.17 μM,且能够通过逆转上皮-间充质转化(EMT)过程阻止胃癌细胞的迁移,并以浓度依赖的方式抑制MKN45细胞的集落形成。值得注意的是,与化合物6y相比,HJ445A的水溶性得到了显著提高,增强了约170倍。此外,HJ445A在体内也显示出了卓越的抗肿瘤效果。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | HJ445A is a highly efficient and selective MYOF inhibitor with excellent water solubility, utilized for the treatment of gastric cancer. In gastric cancer cells MGC803 and MKN45, HJ445A exhibits significant antiproliferative properties with IC50 values of 0.16 μM and 0.14 μM, respectively. The compound binds to the MYOF-C2D domain with a KD value of 0.17 μM and hinders the migration of gastric cancer cells by reversing the epithelial-mesenchymal transition (EMT) process. It also inhibits colony formation in MKN45 cells in a concentration-dependent manner. Remarkably, compared to compound 6y, HJ445A's water solubility is improved by approximately 170 times. Moreover, HJ445A demonstrates superior antitumor effects in vivo. |
别名 | HJ445-A, H-J445-A, H-J445A, HJ445 A, H J445A |
分子量 | 445.52 |
分子式 | C24H27N7O2 |
CAS No. | 3032441-59-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容